ZyVersa Therapeutics Inc. (NASDAQ: ZVSA)
$4.45
-0.4500 ( -9.18% ) 107.2K
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
Market Data
Open
$4.45
Previous close
$4.90
Volume
107.2K
Market cap
$3.68M
Day range
$4.33 - $5.44
52 week range
$3.41 - $90.65
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 19 | Dec 11, 2023 |
8-k | 8K-related | 14 | Nov 30, 2023 |
8-k | 8K-related | 12 | Nov 17, 2023 |
10-q | Quarterly Reports | 61 | Nov 14, 2023 |
8-k | 8K-related | 12 | Nov 02, 2023 |
8-k/a | 8K-related | 12 | Sep 20, 2023 |
8-k | 8K-related | 14 | Sep 14, 2023 |
ars | Annual reports | 1 | Sep 13, 2023 |
def | Proxies and info statements | 3 | Sep 13, 2023 |
8-k | 8K-related | 12 | Sep 08, 2023 |